STAT3 and renal cell carcinoma: To test the role of Stat3 in overriding dasatinib inhibition, we treated the RCC cells with CYT387 (Momelotinub ®), a JAK-STAT inhibitor that is currently in clinical trials for myeloproliferative neoplasia [40].